Recovery Stack (Wolverine)

Description

Overview

The Recovery Stack — known in the research community as the “Wolverine” stack — is a two-component research bundle that pairs the synthetic pentadecapeptide BPC-157 with TB-500, a synthetic peptide derived from thymosin β-4 (Tβ4). Both peptides are widely studied in tissue-repair, cell-migration, and angiogenesis literature, and are frequently examined together in preclinical and in-vitro programmes exploring wound-healing and regenerative signalling. This bundle is supplied as two independently characterised lyophilised vials so that laboratories can reconstitute, dose, and assay each peptide separately or in parallel. It is intended strictly for in-vitro and laboratory research and is not for human or veterinary use.

Research Context

BPC-157 is a stable 15-amino-acid fragment derived from a sequence identified in gastric juice protein. Its high proline content is associated with structural rigidity and resistance to enzymatic degradation, which has made it a durable model peptide in cell-culture and animal-model studies of connective-tissue repair. Published work has investigated its effects on tendon fibroblast outgrowth, survival, and migration ex vivo, and on gene-expression changes such as up-regulation of the growth hormone receptor in cultured tendon fibroblasts.

TB-500 is a synthetic peptide based on thymosin β-4, a naturally occurring 43-amino-acid regenerative peptide found in almost all cells and in wound fluid. In the research-peptide field the name “TB-500” is applied both to the full-length Tβ4 sequence and to its acetylated actin-binding active-region fragment (Ac-LKKTETQ, residues 17–23). Researchers investigate Tβ4 as a regulator of actin dynamics and cell migration, with preclinical and in-vitro studies describing accelerated re-epithelialisation, angiogenesis, and collagen deposition in wound-healing models. Pairing it with BPC-157 gives investigators complementary reference tools spanning cytoprotective and angiogenic signalling on one hand and actin-mediated cell migration on the other.

Mechanism of Interest

• BPC-157: in preclinical models, associated with angiogenic signalling pathways (including VEGFR2 and the nitric-oxide axis) and with fibroblast migration mediated by focal-adhesion signalling. In cell culture it has been reported to alter growth hormone receptor expression at both mRNA and protein levels.
• TB-500 (thymosin β-4): studied as an actin-sequestering peptide that promotes cell migration and new blood-vessel formation; laboratory and animal-model data describe increased keratinocyte and endothelial-cell migration, angiogenesis, reduced inflammation, and increased collagen deposition in wound-repair systems.
• Combined interest: the two peptides address distinct but overlapping nodes of tissue-repair signalling — cytoprotection and angiogenesis alongside actin-driven cell migration — which is why they are so frequently co-examined (the “Wolverine” pairing) in research surveys of regenerative pathways.

Specifications

• Format: two separate lyophilised powder vials (BPC-157 and TB-500).
• BPC-157 identity: sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; molecular formula C62H98N16O22; molecular weight 1419.55 g/mol (free base); CAS 137525-51-0.
• TB-500 identity: synthetic peptide based on thymosin β-4 (Tβ4). The name is used in the field for both the full 43-residue sequence (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES; molecular weight ≈4963 g/mol; CAS 77591-33-4) and its acetylated active-region fragment Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ). The exact form and net peptide content for your lot are documented on the accompanying COA.
• Purity: ≥99% by HPLC, confirmed by mass spectrometry; per-batch results reported on the accompanying certificate of analysis (COA).
• Intended use: in-vitro and laboratory research only.

Handling / Reconstitution / Storage

• Store both lyophilised vials sealed at -20°C, protected from light and moisture; peptides in this format are typically stable for extended periods when kept frozen and dry.
• Allow vials to equilibrate to room temperature before opening to limit condensation on the powder.
• Reconstitute each peptide separately with a suitable solvent for the intended assay (bacteriostatic or sterile water is commonly used in the literature).
• Add solvent slowly against the vial wall rather than directly onto the pellet, and swirl gently instead of shaking to preserve peptide integrity.
• Aliquot reconstituted stock to minimise freeze-thaw cycles; keep working solutions refrigerated and use within the timeframe validated by your protocol.

Quality & Verification

Every batch in the Recovery Stack ships with a third-party certificate of analysis documenting identity, HPLC purity, and mass-spectrometry confirmation for each component. Researchers are encouraged to match the batch number on the vial to the COA and to confirm the reported identities before use. G Peptide Labs supplies these materials as research reference compounds for qualified laboratory personnel; no therapeutic, diagnostic, or performance claims are made, and the products are not intended for human or animal administration.

Selected Research

Peer-reviewed references provided for scientific context; they describe laboratory and preclinical findings only.

1. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology (1985) Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS, 2011. PMID: 21030672
2. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules Chang CH, Tsai WC, Hsu YH, Pang JHS, 2014. PMID: 25415472
3. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, Malinda KM, Sidhu GS, Mani H, et al., 1999. PMID: 10469335
4. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, Goldstein AL, Hannappel E, Sosne G, Kleinman HK, 2011. PMID: 22074294